HC Wainwright & Co. analyst Yi Chen reiterates Bausch & Lomb (NYSE:BLCO) with a Buy and m

BLCO advances two eye-health candidates after positive trial results, with combined estimated peak s

Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyein

Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Med

Bausch + Lomb NYSE: BLCO said it plans to advance a dual-action dry eye treatment into Phase III dev

Carl Icahn made no new stock purchases in Q2, trimming stakes in JetBlue and American Electric Power

Liquidation represents 54% of insider's direct equity stake, executed at $16.78 per share following

LAVAL, QC, Aug. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

HC Wainwright & Co. analyst Yi Chen maintains Bausch & Lomb (NYSE:BLCO) with a Buy and ra

UBS analyst Patrick Wood maintains Bausch & Lomb (NYSE:BLCO) with a Buy and raises the price

Bausch + Lomb Corporation (BLCO) Q2 2026 Earnings Call Transcript

Bausch + Lomb NYSE: BLCO reported second-quarter 2026 revenue growth across its vision care, surgica

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.16 per share, in line with the Zacks Con

Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.16 per share which beat the analyst

Bausch & Lomb (NYSE:BLCO) raises FY2026 sales outlook from $5.420 billion-$5.520 billion to $5.4

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

UBS analyst Patrick Wood initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Buy rating an

BLCO launches EyeGility in the United States, pairing preloaded enVista Aspire lenses with smoother

EyeGility is designed for the enVista® family of IOLsOffers balanced push force for smooth delivery,

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

Bausch + Lomb ended BL1107 glaucoma eye drop development after a Phase 2 miss and will focus on a su

Phase 2 study did not meet its primary endpoint.Company will discontinue development of eye drops fo

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

Designed to reduce the operational burden that stands between physicians and their patients.Initial

VAUGHAN, Ontario, & MENLO PARK, Calif.--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO),

Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Ca

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and

Bausch & Lomb (NYSE:BLCO) raises FY2026 sales outlook from $5.375 billion-$5.475 billion to $5.4

Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.08 per share which beat the analyst

enVista Envy is the first diffractive premium IOL from Bausch + Lomb available in EuropeOffers a con

Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and

Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping peopl

In the prospective, multicenter study, investigators at 20 sites across the U.S. enrolled 318 patien

HC Wainwright & Co. analyst Yi Chen maintains Bausch & Lomb (NYSE:BLCO) with a Buy and ra

Barclays analyst Matt Miksic maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight and rais

Stifel analyst Tom Stephan maintains Bausch & Lomb (NYSE:BLCO) with a Hold and raises the pri

Wells Fargo analyst Larry Biegelsen maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight a

Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.32 per share which missed the analys